All In Biotech

Drug Trial Radar · NCT02993406

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant

Last checked: Nov 20, 2026Latest source record: Jan 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 13,970 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

13,970

Actual

Start

Dec 22, 2016

Primary completion

Nov 7, 2022

Study completion Nov 7, 2022

Sponsor

Lead sponsor
Esperion Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
The Cleveland Clinic
First posted
Dec 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant.

Conditions

  • Cardiovascular Diseases
  • Statin Adverse Reaction

Interventions

  • Bempedoic acid 180 mg tabletDrug

    Patients take bempedoic acid 180 mg tablet orally once daily

  • Matching placebo tabletDrug

    Patients take matching placebo tablet orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE)Time frame: Up to 68 months

Locations

1,319 sites in 32 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Pell City, Alabama

  • Site not named

    Tuscumbia, Alabama

  • Site not named

    Chandler, Arizona

  • Site not named

    Cottonwood, Arizona

  • Site not named

    Fountain Hills, Arizona

  • Site not named

    Gilbert, Arizona

  • Site not named

    Glendale, Arizona

  • Site not named

    Glendale, Arizona

  • Site not named

    Mesa, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Beverly Hills, California

  • Site not named

    Carlsbad, California

  • Site not named

    Huntington Beach, California

  • Site not named

    Lincoln, California

  • Site not named

    Long Beach, California

  • Site not named

    Long Beach, California

  • Site not named

    Northridge, California

  • Site not named

    Oceanside, California

  • Site not named

    Rancho Cucamonga, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Ana, California

  • Site not named

    Santa Rosa, California

  • Site not named

    Torrance, California

  • Site not named

    Vista, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Golden, Colorado

  • Site not named

    Littleton, Colorado

  • Site not named

    Loveland, Colorado

  • Site not named

    Hamden, Connecticut

  • Site not named

    Hartford, Connecticut

Showing 40 of 1,319 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.